<DOC>
	<DOC>NCT02073981</DOC>
	<brief_summary>This study is implemented to identify factors having an impact on improvement or exacerbation of non-motor symptoms, to provide information contributing to development of medical care in this field and improvement of patients' QOL, and to clarify the association between the use of istradefylline and non-motor symptoms or QOL.</brief_summary>
	<brief_title>Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients who have wearing off under treatment with levodopacontaining drugs administered at least three times daily Patients who have at least one nonmotor symptom as a complication Patients at least 20 years of age at the time of consent Patients who have given written consent Patients who are receiving outpatient care Patients with dementia or a score of 23 or less on the MiniMental State Examination (MMSE) Patients, in the opinion of the investigator or subinvestigator, having conditions impairing the proper assessment of the MDSUPDRS or PDQ8 (e.g., patients who are receiving treatment for malignant tumor)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
</DOC>